📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
3 articles
AVG GRADE
NEUTRAL
score: 0.33
SENTIMENT
NEUTRAL
TOTAL VIEWS
18
MDGL Stock Analysis & AI Grade: NEUTRAL
3 articles analyzed · Sentiment: NEUTRAL · AI-powered equity research
RECENT COVERAGE · 3 ARTICLES
Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach (NASDAQ:MDGL)
Madrigal Pharmaceuticals (MDGL) faces intensifying competitive pressure in the obesity-treatment space as semaglutide enters the market,...
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript
MDGL conducted its Q2 2026 earnings call on July 30, 2026, presenting quarterly operational and financial results to investors and...
BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL)
Bank of America reduced its price target on Madrigal Pharmaceuticals (MDGL) by $8 per share, from $550 to $542, while maintaining a...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice